Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2014
September 2014, Vol 5, No 7
September 2014, Vol 5, No 7
Arzerra (Ofatumumab) Receives FDA Approval for Patients with Previously Untreated Chronic Lymphocytic Leukemia for Use in Combination with Chlorambucil
By
Lisa A. Raedler, PhD, RPh
Drug Updates
September 2014, Vol 5, No 7
Chronic lymphocytic leukemia (CLL), the most common type of leukemia in adults, is a cancer that predominantly affects the B-cell lymphocytes.
Read Article
BRAF Protein Expression Potential New Marker for Mortality Risk in Melanoma
By
Rosemary Frei, MSc
Melanoma
September 2014, Vol 5, No 7
Toronto, Ontario—BRAF protein expression is correlated with melanoma progression and poor patient survival, according to recent studies that were reviewed at the 2014 Canadian Dermatology Association annual conference.
Read Article
Comparative Effectiveness Research Helps Define Value in Cancer Care
By
Wayne Kuznar
Comparative Effectiveness Research
September 2014, Vol 5, No 7
Los Angeles, CA—Comparative effectiveness research (CER) can be beneficial to determining value in cancer therapies, but challenges remain in applying this approach in oncology.
Read Article
Payer Challenges in Oncology: Establishing Standards and Access to Quality Care
By
Wayne Kuznar
September 2014, Vol 5, No 7
Los Angeles, CA—Payers are scrambling to devise effective strategies to cope with rapidly changing access to quality cancer care as a result of escalating costs. At the Fourth Annual Conference of the Association for Value-Based Cancer Care, John Fox, MD, MHA, Associate Vice President of Medical Affairs at Priority Health, Grand Rapids, MI, tackled changing access and payer challenges in oncology.
Read Article
Improving the Value Paradigm in Drug Development Will Require More Efficient Clinical Trials, New Biomarkers
By
Wayne Kuznar
September 2014, Vol 5, No 7
Los Angeles, CA—Much remains to be done to usher in the era of personalized healthcare, including better methods of drug development, said presenters at the Fourth Annual Conference of the Association for Value-Based Cancer Care.
Read Article
FDA Approves First Anti–PD-1: Pembrolizumab Indicated for Advanced Melanoma
FDA Approvals, News & Updates
September 2014, Vol 5, No 7
The FDA approved the first anti–programmed death receptor-1 (PD-1) therapy, pembrolizumab (Keytruda; Merck), for patients with unresectable or metastatic melanoma and disease progression after treatment with other melanoma therapy, such as ipilimumab, or, for a patient with BRAF V600 mutation, after BRAF inhibitor therapy.
Read Article
Bortezomib Receives New FDA Indication for Retreatment of Patients with Myeloma
FDA Approvals, News & Updates
September 2014, Vol 5, No 7
Read Article
Payment Reform Requires Abandoning the Fee-for-Service Approach
By
Robert Osborne
Value in Oncology
September 2014, Vol 5, No 7
Chicago, IL—The oncology community has taken a leadership role in payment reform and must retain that position as the pressure mounts for fee-for-service (FFS) alternatives, according to Mark B. McClellan, MD, PhD, Director, Health Care Innovation and Value Initiative, Brookings Institution, Washington, DC, and former Commissioner of the FDA.
Read Article
Maximizing Value and Quality in Gynecologic Cancer Care—Work in Progress
By
Wayne Kuznar
Value in Oncology
September 2014, Vol 5, No 7
Chicago, IL—Comparative effectiveness research (CER) and cost-effectiveness analyses have helped to define value as it relates to gynecologic oncology, said speakers during an education session on maximizing value and quality in gynecologic cancer care, at the 2014 American Society of Clinical Oncology meeting.
Read Article
Cost Burden Follows Patients with Cancer into Survivorship
By
Charles Bankhead
Economics & Value
,
Economics of Cancer Care
,
Survivorship
,
Policies & Guidelines
September 2014, Vol 5, No 7
The high cost of cancer care follows patients well into survivorship, as annual medical costs and losses in productivity exceed those of people without cancer by 50% to 100%, a study for the Centers for Disease Control and Prevention (CDC) showed (Ekwueme DU, et al. MMWR Morb Mortal Wkly Rep. 2014;63:505-510).
Read Article
Page 2 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma